Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(6)
Alzheimer Disease
Central Nervous System
Cerebrospinal Fluid
Enzyme
Protein Metabolism
Amyloid Precursor Protein
Related Publications
(1)
In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid Metabolism and Half-Life
Subscribe
Academic
Publications
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo,10.1038/nm1438,Nature Medicine,Ling Y Munsell,John C Morris,R
Edit
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
(
Citations: 65
)
BibTex
|
RIS
|
RefWorks
Download
Ling Y Munsell
,
John C Morris
,
Robert Swarm
,
Kevin E Yarasheski
,
David M Holtzman
,
Randall J Bateman
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-β (Aβ) in the brain and disease-causing mutations in
amyloid precursor protein
or in enzymes that produce Aβ indicate dysregulation of production or clearance of Aβ. Whether dysregulation of Aβ synthesis or clearance causes the most common form of
Alzheimer disease
(sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human
central nervous system
(CNS). We report the first measurements of the fractional production and clearance rates of Aβ in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in
protein metabolism
that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
Journal:
Nature Medicine - NATURE MED
, vol. 12, no. 7, pp. 856-861, 2006
DOI:
10.1038/nm1438
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
dx.doi.org
)
(
www.nature.com
)
(
web.sapmed.ac.jp
)
Citation Context
(8)
... The total production of amyloid-β in the human brain can be assessed by extrapolating from rodent cell culture experiments and potentially from SILK technolog
...
Marc Mercken
,
et al.
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal f...
... Additionally, the persistence times measured here for complexes between
clusterin
and
Aβ
1−40
oligomers (from 50 h to greater than 200 h) are long enough to allow for crucial
in vivo
processes such as
Aβ
1−40
production (~15 h),
Aβ
1−40
clearance (~14 h) and astrocytic endocytosis (12−24 h
...
Priyanka Narayan
,
et al.
The extracellular chaperone clusterin sequesters oligomeric forms of t...
...The recent progress from Bateman and colleagues (
6
, 7) in labeling APP ( amyloid precursor protein) with 13C leucine may provide an alternate means of establishing full antagonism of Aß formation even in the presence of some continued concentration of soluble Aß in the CSF...
W. Z. Potter
.
Dose ranging for trials through biomarkers of drug effects
...and ∼8–9 hours in human CNS
...
Jack Waters
,
et al.
The Concentration of Soluble Extracellular Amyloid-beta Protein in Acu...
...3% per hou
...
Guojun Bu
.
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, p...
References
(19)
In Vivo Metabolism of ApoB, ApoA-I, and VLDL Triglycerides in a Form of Hypobetalipoproteinemia Not Linked to the ApoB Gene
(
Citations: 10
)
Nizar Elias
,
Bruce W. Patterson
,
Gustav Schonfeld
Published in 2010.
Association of missense and 5 - splice - site mutations in tau with the inherited dementia FTDP - 17
(
Citations: 773
)
M Hutton
,
Cl Lendon
,
P Rizzu
,
M Baker
,
S Froelich
,
H Houlden
,
Pickering Brown S
,
S Chakraverty
,
A Isaacs
,
A Grover
,
J Hackett
,
J Adamson
http://academic.research.microsoft.com/io.ashx?type=5&id=4145606&selfId1=0&selfId2=0&maxNumber=12&query=
Journal:
Nature
, 1998
Alzheimer's Disease: Genes, Proteins, and Therapy
(
Citations: 1226
)
DENNIS J. SELKOE
In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid Metabolism and Half-Life
(
Citations: 68
)
John R. Cirrito
,
Patrick C. May
,
Mark A. O'Dell
,
Jennie W. Taylor
,
Maia Parsadanian
,
Jeffrey W. Cramer
,
James E. Audia
,
Jeffrey S. Nissen
,
Kelly R. Bales
,
Steven M. Paul
,
Ronald B. DeMattos
,
David M. Holtzman
Published in 2003.
Use of stable isotope labeling technique and mass isotopomer distribution analysis of [13C]palmitate isolated from surfactant disaturated phospholipids to study surfactantin vivo kinetics in a premature infant
(
Citations: 5
)
Assaad Merchak
,
Bruce W. Patterson
,
Kevin E. Yarasheski
,
Aaron Hamvas
Journal:
Journal of Mass Spectrometry - J MASS SPECTROMETRY
, vol. 35, no. 6, pp. 734-738, 2000
Sort by:
Citations
(65)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
(
Citations: 1
)
Marc Mercken
,
Bart De Strooper
,
Eric Karran
Journal:
Nature Reviews Drug Discovery - NAT REV DRUG DISCOV
, vol. 10, no. 9, pp. 698-712, 2011
The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β1−40 peptide
Priyanka Narayan
,
Angel Orte
,
Richard W Clarke
,
Benedetta Bolognesi
,
Sharon Hook
,
Kristina A Ganzinger
,
Sarah Meehan
,
Mark R Wilson
,
Christopher M Dobson
,
David Klenerman
Journal:
Nature Structural & Molecular Biology - NAT STRUCT MOL BIOL
, vol. 19, no. 1, pp. 79-83, 2011
Obama Deficit Plan Aims to Strengthen Payment Board
ALICIA AULT
Journal:
Internal Medicine News
, vol. 44, no. 7, pp. 7-7, 2011
Dose ranging for trials through biomarkers of drug effects
(
Citations: 2
)
W. Z. Potter
Journal:
Journal of Nutrition Health & Aging - J NUTR HEALTH AGING
, vol. 14, no. 4, pp. 310-311, 2010
The role of microglia in amyloid clearance from the AD brain
(
Citations: 12
)
C. Y. Daniel Lee
,
Gary E. Landreth
Journal:
Journal of Neural Transmission - J NEURAL TRANSM
, vol. 117, no. 8, pp. 949-960, 2010